Understanding genetic factors in aggressive prostate cancer
Official title: Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
Funded at University of Adelaide · NIH-10926904 · Data updated 2026-11-12
This study is looking at the genes in tumor samples from men with aggressive hormone-sensitive prostate cancer to find clues that can help predict how well they will respond to treatment, with the hope of creating more personalized care for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Adelaide NIH-funded |
| Lab location | 1 site (Adelaide, Australia) |
| Project start | May 1, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $342,087 |
| NIH project number | 5R01CA238020-05 |
| Project ID | NIH-10926904 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic hormone-sensitive prostate cancer who have participated in the referenced clinical trials.
✕Less likely to help
Patients with non-aggressive prostate cancer or those who have not undergone hormonal therapy may not benefit from this research.
What this research studies
This research investigates the genetic profiles of tumor samples from patients with aggressive hormone-sensitive prostate cancer to identify biomarkers that predict treatment responses. By analyzing samples from two major clinical trials, the study aims to uncover how mutations in specific tumor suppressor genes affect patient outcomes. The goal is to enhance the understanding of why some patients respond well to hormonal therapies while others do not, ultimately leading to more personalized treatment approaches. Patients involved in the trials have already contributed valuable data that will be analyzed over the next several years.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with aggressive prostate cancer, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promising results in identifying genetic markers that influence treatment responses in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Adelaide
Adelaide, Australia Active
Researchers
- Principal investigator: Sweeney, Christopher J — University of Adelaide
- Study coordinator: Sweeney, Christopher J
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.